Quazepam has fewer side effects than other benzodiazepines and less potential to induce [[drug tolerance|tolerance]] and [[rebound effects]].<ref>{{cite journal |vauthors=Barnett A, Iorio LC, Ongini E |title=The sedative-hypnotic properties of quazepam, a new hypnotic agent |journal=Arzneimittelforschung |volume=32 |issue=11 |pages=1452–6 |year=1982 |pmid=6129856 |doi= |url=}}</ref><ref>{{cite journal |author=Lader M |title=Rebound insomnia and newer hypnotics |journal=Psychopharmacology |volume=108 |issue=3 |pages=248–55 |year=1992 |pmid=1523276 |doi= 10.1007/BF02245108|url=}}</ref> There is significantly less potential for quazepam to induce [[respiratory depression]] or to adversely affect motor coordination than other [[benzodiazepines]].<ref>{{cite journal |vauthors=Murray A, Bellville JW, Comer W, Danielson L |title=Respiratory effects of quazepam and pentobarbital |journal=J Clin Pharmacol |volume=27 |issue=4 |pages=310–3 |date=April 1987 |pmid=2890670 |doi= 10.1002/j.1552-4604.1987.tb03020.x|url=}}</ref> The different side effect profile of quazepam may be due to its more selective binding profile to type 1 benzodiazepine receptors.<ref>{{cite journal |vauthors=Billard W, Crosby G, Iorio L, Chipkin R, Barnett A |title=Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand |journal=Life Sci. |volume=42 |issue=2 |pages=179–87 |year=1988 |pmid=2892106 |doi= 10.1016/0024-3205(88)90681-9|url=}}</ref><ref>{{cite journal |vauthors=Wamsley JK, Hunt MA |title=Relative affinity of quazepam for type-1 benzodiazepine receptors in brain |journal=J Clin Psychiatry |volume=Suppl |issue= |pages=15–20 |series=52 |date=September 1991 |pmid=1680119 |doi= |url=}}</ref>

 
*[[Ataxia]]<ref>{{cite journal |vauthors=Martinez HT, Serna CT |title=Short-term treatment with quazepam of insomnia in geriatric patients |journal=Clin Ther |volume=5 |issue=2 |pages=174–8 |year=1982 |pmid=6130842 |doi= |url=}}</ref>

 
*Daytime [[somnolence]]<ref>{{cite journal |vauthors=Mendels J, Stern S |title=Evaluation of the short-term treatment of insomnia in out-patients with 15 milligrams of quazepam |journal=J. Int. Med. Res. |volume=11 |issue=3 |pages=155–61 |year=1983 |pmid=6347747 |doi= |url=}}</ref>

 
*[[Hypokinesia]]<ref>{{cite journal |vauthors=Aden GC, Thatcher C |title=Quazepam in the short-term treatment of insomnia in outpatients |journal=J Clin Psychiatry |volume=44 |issue=12 |pages=454–6 |date=December 1983 |pmid=6361006 |doi= |url=}}</ref>

 
*[[Cognitive]] and performance impairments<ref>{{cite journal |vauthors=Schaffler K, Kauert G, Wauschkuhn CH, Klausnitzer W |title=Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam |journal=Arzneimittelforschung |volume=39 |issue=2 |pages=276–83 |date=February 1989 |pmid=2567171 |doi= |url=}}</ref>

 

